Evidence map›Paper›PMID 30233582›Full record

ArticleFrontiers in immunology2018

Lipidomimetic Compounds Act as HIV-1 Entry Inhibitors by Altering Viral Membrane Structure.

Jon Ander Nieto-Garai, Bärbel Glass, Carmen Bunn, Matthias Giese, Gary Jennings, Beate Brankatschk, Sameer Agarwal, Kathleen Börner, F Xabier Contreras, Hans-Joachim Knölker and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Network Pharmacology-Guided Identification ofInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Cholesterol in the Viral Membrane is a Molecular Switch Governing HIV-1 Env Clustering.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Article
  7. Article
  8. Article
  9. Review
  10. Targeting Lipid Rafts as a Strategy Against Coronavirus.Frontiers in cell and developmental biology · 2020
    Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 2 countries.

Jon Ander Nieto-GaraiDepartamento de Bioquímica y Biología Molecular, Instituto Biofisika (CSIC, UPV/EHU), Universidad del País Vasco, Bilbao, Spain.
Bärbel GlassDepartment of Infectious Diseases, Virology, Universitätsklinikum Heidelberg, Heidelberg, Germany.
Carmen BunnJADO Technologies, Dresden, Germany.
Matthias GieseJADO Technologies, Dresden, Germany.
Gary JenningsJADO Technologies, Dresden, Germany.
Beate BrankatschkJADO Technologies, Dresden, Germany.
Sameer AgarwalJADO Technologies, Dresden, Germany.
Kathleen BörnerDepartment of Infectious Diseases, Virology, Universitätsklinikum Heidelberg, Heidelberg, Germany.
F Xabier ContrerasDepartamento de Bioquímica y Biología Molecular, Instituto Biofisika (CSIC, UPV/EHU), Universidad del País Vasco, Bilbao, Spain.
Hans-Joachim KnölkerJADO Technologies, Dresden, Germany.
Claudia ZanklJADO Technologies, Dresden, Germany.
Kai SimonsMax Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany.
Cornelia SchroederJADO Technologies, Dresden, Germany.
Maier LorizateDepartamento de Bioquímica y Biología Molecular, Instituto Biofisika (CSIC, UPV/EHU), Universidad del País Vasco, Bilbao, Spain.
Hans-Georg KräusslichDepartment of Infectious Diseases, Virology, Universitätsklinikum Heidelberg, Heidelberg, Germany.
TU Dresden · DEUniversity Hospital Heidelberg · DEUniversity of the Basque Country · ESHeidelberg University · DEIkerbasque · ESMax Planck Institute of Molecular Cell Biology and Genetics · DEPaul Langerhans Institute Dresden · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The envelope of Human Immunodeficiency Virus type 1 (HIV-1) consists of a liquid-ordered membrane enriched in raft lipids and containing the viral glycoproteins. Previous studies demonstrated that changes in viral membrane lipid composition affecting membrane structure or curvature can impair infectivity. Here, we describe novel antiviral compounds that were identified by screening compound libraries based on raft lipid-like scaffolds. Three distinct molecular structures were chosen for mode-of-action studies, a sterol derivative (J391B), a sphingosine derivative (J582C) and a long aliphatic chain derivative (IBS70). All three target the viral membrane and inhibit virus infectivity at the stage of fusion without perturbing virus stability or affecting virion-associated envelope glycoproteins. Their effect did not depend on the expressed envelope glycoproteins or a specific entry route, being equally strong in HIV pseudotypes carrying VSV-G or MLV-Env glycoproteins. Labeling with laurdan, a reporter of membrane order, revealed different membrane structure alterations upon compound treatment of HIV-1, which correlated with loss of infectivity. J582C and IBS70 decreased membrane order in distinctive ways, whereas J391B increased membrane order. The compounds' effects on membrane order were reproduced in liposomes generated from extracted HIV lipids and thus independent both of virion proteins and of membrane leaflet asymmetry. Remarkably, increase of membrane order by J391B required phosphatidylserine, a lipid enriched in the HIV envelope. Counterintuitively, mixtures of two compounds with opposite effects on membrane order, J582C and J391B, did not neutralize each other but synergistically inhibited HIV infection. Thus, altering membrane order, which can occur by different mechanisms, constitutes a novel antiviral mode of action that may be of general relevance for enveloped viruses and difficult to overcome by resistance development.

Indexed as

Antiviral AgentsBiomimetic Materialsenv Gene Products, Human Immunodeficiency VirusFatty AcidsHEK293 CellsHIV-1HIV InfectionsHumansLipidsMembrane MicrodomainsMolecular StructureSphingosineSterolsVirulenceVirus InternalizationAntiviral Agentsenv Gene Products, Human Immunodeficiency VirusFatty AcidsLipidsSphingosineSterolsHIV-1 envelopeHIV fusion inhibitorslaurdanlipidomimeticslipid raft modulationmembrane orderphosphatidylserine

Identifiers

PMID30233582
PMCPMC6131562
OpenAlexW2890011138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.